Wunderlich Reports Growing Confidence In Abiomed's Project II Data

In a report published by Wunderlich Securities, the firm has growing confidence in Abiomed ABMD regarding Project II data.

Wunderlich reported that it hosted two days of meetings with Abiomed management late last week. “We came away from the meetings with increased confidence related to the April 3 release of the full Protect II trial data. The data on 430 patients enrolled in the trial will be presented at the American College of Cardiology (ACC) conference in New Orleans. We continue to believe that, despite the termination of the trial, the full presentation of the data will prove to be a positive catalyst for Impella usage and for ABMD shares. We would be buyers of ABMD shares in advance of the ACC presentation.”

Abiomed closed yesterday at $13.45.